1. Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient.
- Author
-
Wu, Yanan, Zhang, Runfang, Yuan, Guangbo, He, Lingyu, Dai, Xiaohu, Chuan, Hongyun, Wang, Mingqing, Liu, Jing, Xu, Lilan, Liao, Guoyang, Li, Weidong, and Zhou, Jian
- Subjects
- *
AMINO acid residues , *IMMUNE serums , *ORAL vaccines , *POLIOVIRUS , *IMMUNE response - Abstract
Background: The serotype 2 oral poliovirus vaccine (OPV2) can revert to regain wild-type neurovirulence and spread, causing the emergence of vaccine-derived poliovirus (VDPV2) and immunodeficiency-related vaccine-derived polioviruses (iVDPVs). In the United States, testing carried out by the CDC of type II iVDPV (iVDPV2) with human immune serum from the vaccine has shown that the presence of the virus poses a threat to eradication efforts. Methods: We analyzed the major neutralization sites of VP1, VP2, and VP3 of the iVDPV using bioinformatics techniques and homology modeling (SWISS-MODEL). The three amino acid residues 679, 680, and 141 of the P1 region changed, which had an impact on the spatial conformation of the viral-neutralizing site. We tested polio-vaccinated human sera and rabbit anti-Sabin II polyantibodies against a panel of iVDPV pseudoviruses. Results: The results demonstrated that the serum's capacity to neutralize mutant pseudoviruses diminished when amino acid substitutions were introduced into the P1 encapsidated protein, particularly when 141 and 679 were mutated together. This study emphasizes the significance of continually monitoring individuals who are known to be immunocompromised and maintaining high vaccination rates in OPV-using communities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF